COMPANY OVERVIEW

Allarity Therapeutics (NASDAQ: ALLR) is a clinical-stage precision medicine company headquartered in Boston, Massachusetts. The company is dedicated to revolutionizing cancer treatment by developing and commercializing targeted therapies and companion diagnostics that provide a personalized approach to cancer care. Leveraging its proprietary Drug Response Predictor (DRP®) technology, Allarity aims to enhance patient outcomes by accurately predicting individual responses to specific cancer treatments. The company's lead therapeutic candidate, stenoparib, exemplifies this innovative approach, showing promise in a Phase 2 trial for advanced recurrent ovarian cancer.

KEY CONSIDERATIONS

- **Innovative Technology**: Allarity's DRP® platform predicts patient responses to cancer treatments, improving efficacy and reducing side effects.
- **Lead Drug Candidate**: Stenoparib, a dual PARP and tankyrase inhibitor, is in a Phase 2 trial for advanced recurrent ovarian cancer.
- **Strategic Collaborations**: The company collaborates with leading institutions and companies to advance its drug development and commercialization efforts.
- **Experienced Leadership**: Led by seasoned executives with extensive biotech and pharmaceutical industry backgrounds, including CEO Thomas Jensen.
- **Market Potential**: Positioned to capitalize on the growing global demand for precision oncology solutions, targeting significant unmet medical needs.

PRECISION ONCOLOGY FOR BETTER OUTCOMES

Innovative Technology Addressing Unmet Medical Needs

PROPRIETARY TECHNOLOGY

The DRP® platform enhances precision oncology by predicting patient responses to specific treatments.

ADVANCED THERAPEUTICS

Stenoparib, a dual PARP and tankyrase inhibitor, targets advanced recurrent ovarian cancer.

STRATEGIC COLLABORATIONS

Collaborates with top institutions to co-develop and advance promising cancer treatments.

EXPERIENCED LEADERSHIP

Allarity is led by experts with extensive backgrounds in biotech and pharmaceuticals.

CLINICAL VALIDATION

Phase 2 trials show promising results for stenoparib in treating advanced ovarian cancer.

GLOBAL REACH

With operations in the US and Europe, Allarity has access to precision oncology solutions worldwide.

NASDAQ: ALLR

allarity™
THERAPEUTICS

REVOLUTIONIZING CANCER TREATMENT WITH PRECISION MEDICINE

Allarity Therapeutics (NASDAQ: ALLR) is at the forefront of precision oncology, developing targeted therapies and companion diagnostics to enhance the effectiveness of cancer treatments. Using its proprietary Drug Response Predictor (DRP®) technology, Allarity can identify which patients are most likely to benefit from specific therapies, thereby improving treatment outcomes and minimizing side effects. This personalized approach to cancer care represents a significant advancement in oncology.

One of Allarity's most promising therapeutic candidates is stenoparib, a dual PARP and tankyrase inhibitor currently in a Phase 2 clinical trial for advanced, recurrent ovarian cancer. Stenoparib has shown encouraging results, demonstrating the potential to provide a much-needed treatment option for patients with limited alternatives. The success of this candidate underscores the efficacy of Allarity's DRP® technology in predicting patient response and tailoring treatments to individual needs.

Allarity's strategic collaborations with leading institutions and biopharmaceutical companies further enhance its drug development capabilities. These partnerships enable the company to leverage external expertise and resources, accelerating the advancement of its therapeutic pipeline. Additionally, Allarity's global operations in the US and Europe provide a broad platform for clinical trials and commercialization efforts, ensuring that innovative treatments reach patients worldwide.

Led by a team of experienced executives with extensive backgrounds in biotechnology and pharmaceuticals, Allarity is well-positioned for sustained growth and innovation. The leadership team's strategic vision and operational acumen have been instrumental in navigating the complexities of the precision medicine landscape. As the company continues to advance its pipeline and expand its reach, Allarity remains committed to transforming the future of cancer treatment through personalized medicine.

3,000+
Gene expression data from patient tumors analyzed

$22 BILLION
Estimated PARP inhibitor market value by 2028

35+
Clinical trial validation across various cancer types

2004
Year of founding in Denmark, as Medical Prognosis Institute A/S

NASDAQ: ALLR

allarity™
THERAPEUTICS

THOMAS JENSEN
CHIEF EXECUTIVE OFFICER, FOUNDER

- Chief Executive Officer since December 2023: Leading the company's strategic direction and operations.
- Co-Founder of Allarity Therapeutics A/S in 2004: Instrumental in establishing the company and its core technologies.
- Developed and leads investor relations operations: Securing operational financing and fostering business growth.
- Inventor of key molecular biological guidelines: Techniques for high-quality reproducible RNA extraction and downstream processing, foundational to the DRP® platform.
- Former Chief Technology Officer: Oversaw the development of Allarity's proprietary technologies from 2004 to 2020.

JOAN Y BROWN
CHIEF FINANCIAL OFFICER

- Chief Financial Officer since July 2022: Overseeing financial operations and regulatory compliance.
- Director of Financial Reporting since September 2021: Assisted in the company's move to the U.S. Nasdaq.
- Over 20 years of experience: Specializes in financial and regulatory reporting, audit experience, and full-cycle accounting.
- Director of Prudential Supervision at FICOM: Managed financial oversight for financial institutions in Vancouver, BC, Canada.
- Registered CPA and Chartered Accountant: Holds certifications in both Canada and the State of Illinois.

STEEN KNUDSEN
CHIEF SCIENTIFIC OFFICER, FOUNDER

- Chief Scientific Officer since 2006: Leads scientific research and development efforts at Allarity.
- Inventor of the DRP® Platform: Developed the Drug Response Prediction Platform, central to Allarity's personalized medicine approach.
- Former Professor of Systems Biology: Extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology.
- Co-founder of Allarity Therapeutics A/S in 2004: Played a key role in the company's initial development and scientific direction.
- Educational Background: Holds an M.Sc. in Engineering and a Ph.D. in Microbiology, with postdoctoral training in computational biology from Harvard Medical School.

NASDAQ: ALLR

allarity ™
THERAPEUTICS